Emmessar Biotech (524768)

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• ROCE of 12.61% indicates a modest operating return on capital employed.
• Piotroski F-Score of 6/9 suggests the financial health is not uniformly poor.
• Reported 500% profit growth, though from a small base, hints at an earnings recovery attempt.
• Book value of ₹16.30 provides some tangible asset backing, albeit below the market price.

Concerns

• Latest quarter sales and net profit are ₹0 Cr, so there is no visible operating earnings stream.
• Sales growth is -10%, and commodity chemicals generally lack pricing power and a durable moat.
• At P/E 39.27 and P/B 2.64 with ROE of only 4.27%, the valuation is rich relative to profitability.
• No dividend, undisclosed promoter holding, and a ₹22 Cr market cap add governance and liquidity risk.

AI Analysis

When I look at Emmessar Biotech, I see a small commodity chemical company selling for ₹42.96 with a market cap of only ₹22 Cr. That market cap immediately tells me I must be careful: small, illiquid, and often ignored by serious investors. The reported profit growth of 500% catches the eye, but Graham taught me to be skeptical of percentages from a tiny base. With latest quarter sales at ₹0 Cr and net profit at ₹0 Cr, there is no current operating engine to value. Annual profit implied by P/E 39.27 is perhaps around ₹0.56 Cr, which is too small and too volatile to justify a multiple. The business quality is weak: commodity chemicals generally have no pricing power or moat, and the 10% sales decline reinforces that. ROE is just 4.27%, far below what I would require, while P/B is 2.64. Paying 2.64 times book for a 4.27% return on equity is not a margin-of-safety purchase. ROCE of 12.61% and a Piotroski score of 6/9 suggest some operational discipline, but without meaningful revenue, these ratios are unreliable. There is no dividend, so the investor receives no compensation while waiting. The stock sits at the high end of its 52-week range, which tells me the market has already noticed something. But a rising price is not a thesis. I need evidence of sustainable earnings, not a single quarter's anomaly. The PEG of 0.08 is misleading because growth is from a negligible base. If I were to invest here, I would demand proof that sales return and cash profits are durable. Until then, this is a pass. There is simply too much uncertainty and too little margin of safety for a value investor.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer